Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:48 PM
Ignite Modification Date:
2025-12-24 @ 11:48 PM
NCT ID:
NCT00907751
Eligibility Criteria:
Inclusion Criteria:
* Microangiopathic hemolytic anemia (\< 12 g/dL) with thrombocytopenia \<50 G/L, and mild or no renal failure (Serum creatinine \< 150 µmol/L),
* negative Beta HCG and ongoing contraception during treatment and during the 24 months following the last infusion of rituximab,
* refractory TTP (after 4 days of standard treatment)
* \> 18 year old
* and signed written informed consent.
Exclusion Criteria:
* Hemolytic uremic syndrome (platelet count ³ 50 G/L and serum creatinine ³ 150 micromol/L),
* TTP associated with another condition (HIV infection, cancer and/or chemotherapy, transplantation),
* previous treatment with vincristine or cyclophosphamide or other immunomodulatory drugs (except steroids), within 2 months before inclusion ;
* ongoing or planned pregnancy, lactation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00907751
Study Brief:
Protocol Section:
NCT00907751